GLFD Guilford Pharmaceuticals (MM)

Guilford to Webcast Conference Call on June 21, 2004 BALTIMORE, June 18 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD) announced today that it will host a conference call to discuss its license agreement with Symphony Neuro Development Company (SNDC) relating to U.S. rights to GPI 1485, as announced on June 18, 2004. Craig Smith, Chairman, President and Chief Executive Officer of Guilford, will host the call. What: Guilford Corporate Update conference call When: Monday, June 21 at 11:00 a.m. Eastern Time Where: http://www.guilfordpharm.com/ How: Dial-in to 1-800-915-4836 (U.S.) or 1-973-317-5319 (international) to listen to the call. In addition to the live call, there will be a 24-hour audio archive that may be accessed by dialing 1-800-428-6051 (U.S.) or 1-973-709-2089 (international). The conference ID number is 362451. Or access the live call or the fourteen-day archive on the Internet by logging on to http://www.guilfordpharm.com/. Please connect to Guilford's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to access the webcast. About Guilford Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of products that target the hospital market. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and AGGRASTAT(R) Injection (tirofiban hydrochloride), a glycoprotein GP IIb/IIIa receptor antagonist used for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection. For additional information about GLIADEL(R) Wafer, please visit http://www.guilfordpharm.com/ under Products / Marketed Products / GLIADEL; and for AGGRASTAT(R), please see http://www.aggrastat.com/. Contact: Guilford: Stacey Jurchison Director, Corporate Communications 410-631-5022 http://www.guilfordpharm.com/ DATASOURCE: Guilford Pharmaceuticals Inc. CONTACT: Stacey Jurchison, Director, Corporate Communications, Guilford Pharmaceuticals, +1-410-631-5022 Web site: http://www.guilfordpharm.com/ Company News On-Call: http://www.prnewswire.com/comp/112882.html

Copyright